Dr Gasparetto discusses the management of ocular toxicities associated with belantamab mafodotin, the nuances of dose modification, and the potential for retreatment following toxicity resolution.
Welcome to OncLive On Air®! I’m your host today, Jessica Hergert.
OncLive On Air® is a podcast from OncLive®, which provides oncology professionals with the resources and information they need to provide the best patient care. In both digital and print formats, OncLive® covers every angle of oncology practice, from new technology to treatment advances to important regulatory decisions.
In today’s episode, sponsored by GlaxoSmithKline, we had the pleasure of speaking with Cristina Gasparetto, MD, a professor of medicine and member of the Duke Cancer Institute, to discuss the optimal use of belantamab mafodotin-blmf (Blenrep) in patients with relapsed/refractory multiple myeloma.
In our exclusive interview, Gasparetto discussed the management of ocular toxicities associated with belantamab mafodotin, the nuances of dose modification, and the potential for retreatment following toxicity resolution.
Check back on Mondays and Thursdays for exclusive interviews with leading experts in the oncology field. For more updates in oncology, be sure to visit www.OncLive.com and sign up for our e-newsletters.
OncLive is also on social media. On Twitter, follow us at @OncLive and @OncLiveSOSS. On Facebook, like us at OncLive and OncLive State of the Science Summit and follow our OncLive page on LinkedIn.
If you liked today’s episode of OncLive On Air®, please consider subscribing to our podcast on Apple Podcasts, Spotify, Google Podcasts, Amazon Music, and many of your other favorite podcast platforms,* so you get a notification every time a new episode is posted. While you are there, please take a moment to rate us!
Thanks again for listening to OncLive On Air®.
*OncLive On Air® is available on: Apple Podcasts, Google Podcasts, Spotify, Amazon Music, Audacy, CastBox, Deezer, iHeart, JioSaavn, Listen Notes, Player FM, Podcast Addict, Podchaser, RadioPublic, and TuneIn.
Dr Leypoldt on the Use of Isa-KRd in Newly Diagnosed, High-Risk Multiple Myeloma
Isa-KRd Elicits MRD-Negative Remissions in Newly Diagnosed, High-Risk Myeloma
KIT Inhibitors Lead to Shift in Treatment of Systemic Mastocytosis
Smoldering Multiple Myeloma Management Hinges on the Debate Between Treatment and Observation